Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT04799054 is registered in ClinicalTrials.gov with Ascendis Pharma Oncology Division A/S as lead sponsor.

NCT NCT04799054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04799054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Lead sponsor
Ascendis Pharma Oncology Division A/S
Phase
Phase 1/2
Overall status
Terminated
Start date
March 18, 2021
Completion date
December 2, 2025
Enrollment
188 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, head and neck squamous cell carcinoma hnscc, hpv-associated cancers, locally advanced solid tumor, metastatic solid tumor, neoadjuvant cutaneous squamous cell carcinoma (cscc), neoadjuvant melanoma